Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE

Recruiting now · Not applicable

Conditions studied: Systemic Lupus Erythematosus of Childhood

In brief

Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the extent of renal damage. In pediatric SLE, and particularly in lupus nephritis, activation of the IFN-I pathway has never been studied, nor is it known whether monogenic forms underlie more pronounced interferon activation.

Key facts

Study ID

NCT06586710

Run by

Meyer Children's Hospital IRCCS

People needed

60

Starts

2023-06-07

Expected to finish

2025-12-31

Last updated by the study team

2024-09-19

Who can join

Age: 0 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of SLE arising before the age of majority (until the age of 18 years) according to SLICC and/or EULAR criteria 2019;
• Clinical, laboratory and/or histologic evidence of renal involvement manifested before the age of 18 years;
• Signature of informed consent.

You may not qualify if…

• Onset of renal disease after the age of 18 years;
• SLE secondary to drugs or associated with other diseases such as systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, and other connectivities.

Where it is running

• Meyer Children's Hospital IRCCS — Florence, Italy (enrolling)
• IRCCS Gianna Gaslini — Genova, Italy (enrolling)
• IRCCS Humanitas Research Hospital — Rozzano, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.